(Reuters) -Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a ...
NexCAR19, the world’s first humanised CAR-T therapy developed in India, has made gene therapies affordable and accessible ...
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...
Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the ...
The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as it's ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
UniQure said the U.S. Food and Drug Administration no longer agreed that clinical data for the Dutch company's gene therapy ...
Despite challenges like high production costs and uneven regulations, the region is set to become a hub for cutting-edge ...
The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the ...
In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback